Name

Heranova Lifesciences

Legal name

Heranova Lifesciences Inc.

Website

https://heranova.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Women's Health Diagnostics

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)

akta.pro secondary industries

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

Keywords

• Women's health diagnostics
• Endometriosis blood testing
• Reproductive medicine diagnostics
• MicroRNA biomarker assays
• Fertility diagnostic services

Headquarters

HQ city

Burlington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Testing Services: HerAnova generates revenue through laboratory-developed diagnostic tests (LDTs). HerResolve is offered as a blood-based test for endometriosis detection, currently available at select IVF and reproductive medicine centers. Revenue is derived from test processing and analysis for healthcare providers and patients.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Core offering

Heranova Lifesciences develops and commercializes non-invasive blood-based and microbiome-based diagnostic tests for endometriosis and female fertility, with the core product HerResolve™ integrating multi-omic biomarkers (microRNA, protein, hormone) with a proprietary random forest AI algorithm to confirm endometriosis without surgical laparoscopy. The company also has a development pipeline spanning diagnostic assays (HerEndo, HerBiota, HerTempo, HerReceptivity) and the HerCAPA biphasic in vitro maturation fertility technology platform.

Product overview

Heranova Lifesciences is a Boston-based biotech company offering integrated care solutions for women's health in endometriosis and female fertility. The core commercial product is HerResolve™, a non-invasive blood-based diagnostic test for endometriosis that uses multi-omic biomarker analysis (microRNA, protein, hormone) with machine learning algorithms. The product pipeline includes HerEndo™ (vaginal microbiome-based endometriosis screening), HerBiota™ and HerBiota™-Complete (uterine/vaginal microbiome tests), HerTempo™ (ovarian reserve assessment), HerReceptivity™ (endometrial receptivity test), and HerCAPA™ (hormone-free fertility technology). These diagnostic tests work together as an integrated suite to address the multifactorial nature of endometriosis and infertility.

Differentiator

Problem solved

Functional benefit

Brands

• HerResolve: Non-invasive, LDT-validated blood-based diagnostic test for confirmation of endometriosis in symptomatic women.
• HerEndo
• HerBiota
• HerBiota-Complete
• HerTempo
• HerReceptivity
• HerCAPA

Products and services

• HerResolve™ Non-invasive, LDT-validated, blood-based test that confirms endometriosis in symptomatic women using a multi-omic assay integrating microRNA, protein, and hormone biomarkers analyzed through a proprietary machine learning algorithm. It is for symptomatic women of reproductive age and is ordered by physicians at IVF and reproductive medicine centers.
• HerEndo™ Minimally invasive vaginal swab test providing comprehensive assessment of vaginal microbiome including bacterial and fungal composition and associated antibiotic resistance markers for endometriosis screening using qPCR and next-generation sequencing.
• HerBiota™ NGS-based test to assess uterine microbiome environment for detecting chronic endometritis and other gynecological conditions due to pathogens and/or dysbiosis.
• HerBiota™-Complete NGS-based test assessing both uterine and vaginal microbiome environment to help clinicians provide personalized treatment recommendations for gynecological conditions.
• HerTempo™ Proprietary algorithmic-based ovarian reserve assessment for estimating a woman's remaining childbearing years based on patient-specific clinical information.
• HerReceptivity™ NGS-based test to identify each patient's optimal embryo transplantation time during the IVF process to address recurrent implantation failure.
• HerCAPA™ Biphasic in vitro maturation (CAPA-IVM) technology platform for hormone-free assisted reproduction, designed to mature immature eggs with minimal or no conventional ovarian stimulation medications.

Quantifiable outcome

• AUC of 0.944 (95% CI: 0.892-0.996) demonstrating excellent discriminatory power
• +4 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• Lavima Fertility (Belgium)coreStrategic or Co-development PartnerHerAnova is the exclusive partner of Lavima Fertility for development of HerCAPA biphasic in vitro maturation (CAPA-IVM) technology in Greater China. HerCAPA is designed to mature immature eggs with minimal hormonal stimulation, potentially reducing treatment burden for fertility patients.
• Sichuan Jinxin Xinan Women's and Children's Hospital (China)coreStrategic or Co-development PartnerLeading reproductive medicine center in China conducting clinical studies using HerCAPA technology. The hospital achieved the first healthy live birth using HerCAPA in May 2026, marking a landmark clinical translation achievement.
• Johns Hopkins School of MedicinecoreStrategic or Co-development PartnerClinical site contributing to HerResolve multi-center validation study involving 298 reproductive-age women across US, Europe, and Hong Kong.
• Prince of Wales Hospital of Hong KongcoreStrategic or Co-development PartnerClinical site contributing to HerResolve multi-center validation study involving 298 reproductive-age women across US, Europe, and Hong Kong.
• Kaiser PermanentecoreStrategic or Co-development PartnerClinical site contributing to HerResolve multi-center validation study involving 298 reproductive-age women across US, Europe, and Hong Kong.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• DotLab: DotLab is developing a blood-based microRNA diagnostic test for endometriosis, making it the most directly comparable competitor to Heranova's HerResolve product. Both companies target the same unmet need of non-invasive endometriosis detection using biomarker-based approaches.
• Natera: Natera is a molecular diagnostics company with a strong reproductive health franchise including preconception and prenatal testing. Its use of molecular biomarker technologies (including cell-free DNA) and its commercial footprint in IVF centers makes it a relevant comparable for Heranova's diagnostics pipeline.
• Aspira Women's Health: Aspira Women's Health is a commercial-stage diagnostics company focused on women's health with products for ovarian cancer risk assessment. Its commercial diagnostic approach in a women's health specialty market is structurally similar to Heranova's HerResolve go-to-market model.

Broad incumbents

• CooperSurgical (CooperCompanies): CooperSurgical is a major provider of fertility and women's health products and services including IVF diagnostics and ART-related tools. It is comparable to Heranova because it serves the same IVF and reproductive medicine customer base with diagnostic and treatment solutions across the fertility journey.
• Hologic: Hologic is a large women's health diagnostics company with established products in reproductive health, prenatal screening, and gynecological conditions. Its scale, commercial reach, and FDA-cleared diagnostic portfolio represent both a competitive threat and a potential strategic acquirer for Heranova.
• Myriad Genetics: Myriad Genetics operates a broad molecular diagnostics franchise with women's health products including hereditary cancer and prenatal screening. Its established payer relationships and clinical sales force make it a relevant adjacent comparable in the molecular diagnostics space.
• F. Hoffmann-La Roche: Roche is a global diagnostics and pharmaceutical leader with extensive women's health and reproductive medicine franchises. Penny Wan, Heranova's Chairwoman, is a former Roche executive, and Roche represents both a potential strategic partner and an established comparable in women's health diagnostics.
• GE HealthCare: GE HealthCare provides women's health ultrasound and imaging solutions used in endometriosis evaluation and IVF workflows. Its current imaging dominance in the diagnostic pathway that HerResolve aims to disrupt makes it a key adjacent comparable and potential strategic partner.

Emerging players

• Bio-Techne: Bio-Techne provides research and diagnostic tools including biomarker assay platforms and reproductive health research reagents. Its involvement in biomarker discovery and clinical assay development places it in the same technology category as Heranova's multi-omic diagnostic approach.
• Ferring Pharmaceuticals: Ferring Pharmaceuticals is a leading reproductive medicine company focused on fertility treatments and obstetric products. Its deep IVF customer relationships and CSO Marcel van Duin's prior role make it a relevant strategic comparable in the fertility therapeutics space Heranova is entering with HerCAPA.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Heranovalifesci
• Facebookfacebook.com/profile.php?id=61560810448068
• LinkedInlinkedin.com/company/heranova-lifesciences
• Instagraminstagram.com/heranova_lifesciences

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Heranova Lifesciences